Business Description
Bristol-Myers Squibb Co
NAICS : 325412
SIC : 2834
430 East 29th Street, 14th Floor, New York, NY, USA, 10016
Compare
Compare
Traded in other countries / regions
BMY.Argentina
•
BMYS.Austria
•
BMYB34.Brazil
•
BRM.Germany
•
BMY.Mexico
•
BMY.Switzerland
•
0R1F.UK
•
BMY.USA
Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.31 | |||||
| Equity-to-Asset | 0.33 | |||||
| Debt-to-Equity | 1.32 | |||||
| Debt-to-EBITDA | 2.22 | |||||
| Interest Coverage | 7.22 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 2.62 | |||||
| Beneish M-Score | -2.82 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.4 | |||||
| 3-Year EBITDA Growth Rate | 29.3 | |||||
| 3-Year EPS without NRI Growth Rate | 1.2 | |||||
| 3-Year FCF Growth Rate | 22 | |||||
| 3-Year Book Growth Rate | 24.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | -1.82 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 2.32 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.87 | |||||
| 9-Day RSI | 45.88 | |||||
| 14-Day RSI | 48.93 | |||||
| 6-1 Month Momentum % | 57.21 | |||||
| 12-1 Month Momentum % | 90.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.44 | |||||
| Quick Ratio | 1.34 | |||||
| Cash Ratio | 0.63 | |||||
| Days Inventory | 78.96 | |||||
| Days Sales Outstanding | 59.32 | |||||
| Days Payable | 111.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.79 | |||||
| Dividend Payout Ratio | 0.17 | |||||
| 3-Year Dividend Growth Rate | 7.7 | |||||
| Forward Dividend Yield % | 1.17 | |||||
| 5-Year Yield-on-Cost % | 1.03 | |||||
| 3-Year Average Share Buyback Ratio | -9.9 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 79.13 | |||||
| Operating Margin % | 19.75 | |||||
| Net Margin % | 14.04 | |||||
| ROE % | 19 | |||||
| ROA % | 6.19 | |||||
| ROIC % | 8.78 | |||||
| ROC (Joel Greenblatt) % | 130.26 | |||||
| ROCE % | 10.45 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 24.74 | |||||
| Forward PE Ratio | 6.96 | |||||
| PE Ratio without NRI | 24.74 | |||||
| Shiller PE Ratio | 50.07 | |||||
| Price-to-Owner-Earnings | 13.11 | |||||
| PEG Ratio | 3.09 | |||||
| PS Ratio | 3.46 | |||||
| PB Ratio | 4.88 | |||||
| Price-to-Free-Cash-Flow | 11.49 | |||||
| Price-to-Operating-Cash-Flow | 10.65 | |||||
| EV-to-EBIT | 21.09 | |||||
| EV-to-Forward-EBIT | 9.82 | |||||
| EV-to-EBITDA | 9.72 | |||||
| EV-to-Forward-EBITDA | 9.31 | |||||
| EV-to-Revenue | 4 | |||||
| EV-to-Forward-Revenue | 4.1 | |||||
| EV-to-FCF | 13.22 | |||||
| Price-to-Projected-FCF | 1.2 | |||||
| Price-to-Median-PS-Value | 0.77 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.17 | |||||
| Earnings Yield (Greenblatt) % | 4.74 | |||||
| Forward Rate of Return (Yacktman) % | 17.95 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ARS) | 5,027,992.256 | ||
| EPS (TTM) (ARS) | 318.295 | ||
| Beta | 0 | ||
| Volatility % | 32.26 | ||
| 14-Day RSI | 48.93 | ||
| 14-Day ATR (ARS) | 243.344386 | ||
| 20-Day SMA (ARS) | 7444.275 | ||
| 12-1 Month Momentum % | 90.4 | ||
| 52-Week Range (ARS) | 3635 - 8350 | ||
| Shares Outstanding (Mil) | 2,135.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bristol-Myers Squibb Co Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||